About ascentage pharma group international co ltd - ASPHF
Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
ASPHF At a Glance
Ascentage Pharma Group International Co., Ltd.
Suzhou Industrial Park
Suzhou, Jiangsu 215000
| Phone | 86-512-85557777 | Revenue | 136.26M | |
| Industry | Pharmaceuticals: Major | Net Income | -56,335,039.23 | |
| Sector | Health Technology | 2024 Sales Growth | 334.904% | |
| Fiscal Year-end | 12 / 2025 | Employees | 567 | |
| View SEC Filings |
ASPHF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.97 |
| Price to Book Ratio | 50.719 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -46.072 |
| Enterprise Value to Sales | 13.419 |
| Total Debt to Enterprise Value | 0.127 |
ASPHF Efficiency
| Revenue/Employee | 240,320.312 |
| Income Per Employee | -99,356.33 |
| Receivables Turnover | 10.039 |
| Total Asset Turnover | 0.383 |
ASPHF Liquidity
| Current Ratio | 1.264 |
| Quick Ratio | 1.258 |
| Cash Ratio | 1.081 |
ASPHF Profitability
| Gross Margin | 88.387 |
| Operating Margin | -38.628 |
| Pretax Margin | -40.277 |
| Net Margin | -41.343 |
| Return on Assets | -15.822 |
| Return on Equity | -251.982 |
| Return on Total Capital | -20.958 |
| Return on Invested Capital | -33.852 |
ASPHF Capital Structure
| Total Debt to Total Equity | 642.649 |
| Total Debt to Total Capital | 86.535 |
| Total Debt to Total Assets | 64.691 |
| Long-Term Debt to Equity | 336.66 |
| Long-Term Debt to Total Capital | 45.332 |